Literature DB >> 22768020

The CTSA Pharmaceutical Assets Portal - a public-private partnership model for drug repositioning.

Kate Marusina1, Dean J Welsch, Lynn Rose, Doug Brock, Nathan Bahr.   

Abstract

The Pharmaceutical Assets Portal aims to facilitate industry-academic collaborations for discovery of new indications for compounds no longer being developed by pharmaceutical companies, through eliminating barriers to access such compounds. The Portal's enabling infrastructure includes a national investigator database; a Foci-of-Expertise browser; a material transfer agreement template; and a funding partner. Whereas the goal of creating a shared compound repository remains to be achieved, the Portal has established a mechanism to facilitate future drug repositioning opportunities.

Entities:  

Year:  2011        PMID: 22768020      PMCID: PMC3388510          DOI: 10.1016/j.ddstr.2011.06.006

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN: 1740-6773


  2 in total

1.  Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium.

Authors:  Steven E Reis; Lars Berglund; Gordon R Bernard; Robert M Califf; Garret A Fitzgerald; Peter C Johnson
Journal:  Acad Med       Date:  2010-03       Impact factor: 6.893

2.  The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Authors:  Ruili Huang; Noel Southall; Yuhong Wang; Adam Yasgar; Paul Shinn; Ajit Jadhav; Dac-Trung Nguyen; Christopher P Austin
Journal:  Sci Transl Med       Date:  2011-04-27       Impact factor: 17.956

  2 in total
  9 in total

1.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

2.  What, Where, When and How of COVID-19 Patents Landscape: A Bibliometrics Review.

Authors:  Kunmeng Liu; Xiaoming Zhang; Yuanjia Hu; Weijie Chen; Xiangjun Kong; Peifen Yao; Jinyu Cong; Huali Zuo; Jian Wang; Xiang Li; Benzheng Wei
Journal:  Front Med (Lausanne)       Date:  2022-07-01

3.  Computer-Aided Identification of Anticonvulsant Effect of Natural Nonnutritive Sweeteners Stevioside and Rebaudioside A.

Authors:  Mauricio E Di Ianni; María E Del Valle; Andrea V Enrique; María A Rosella; Fiorella Bruno; Luis E Bruno-Blanch; Alan Talevi
Journal:  Assay Drug Dev Technol       Date:  2015 Jul-Aug       Impact factor: 1.738

4.  Warning letters to sponsor-investigators at academic health centres - the regulatory "canaries in a coal mine".

Authors:  Erin K O'Reilly; M E Blair Holbein; Jelena P Berglund; Amanda B Parrish; Mary-Tara Roth; Bruce K Burnett
Journal:  Clin Invest Med       Date:  2013-12-01       Impact factor: 0.825

5.  Repurposing FDA Approved Drugs as JNK3 Inhibitor for Prevention of Neuroinflammation Induced by MCAO in Rats.

Authors:  Zikra Zulfiqar; Fawad Ali Shah; Shagufta Shafique; Abdullah Alattar; Tahir Ali; Arooj Mohsin Alvi; Sajid Rashid; Shupeng Li
Journal:  J Inflamm Res       Date:  2020-12-24

6.  Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research.

Authors:  Ciska Verbaanderd; Ilse Rooman; Isabelle Huys
Journal:  Trials       Date:  2021-05-04       Impact factor: 2.279

7.  Drug repurposing: a systematic review on root causes, barriers and facilitators.

Authors:  Nithya Krishnamurthy; Alyssa A Grimshaw; Sydney A Axson; Sung Hee Choe; Jennifer E Miller
Journal:  BMC Health Serv Res       Date:  2022-07-29       Impact factor: 2.908

Review 8.  Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases.

Authors:  Minna Allarakhia
Journal:  Drug Des Devel Ther       Date:  2013-08-08       Impact factor: 4.162

Review 9.  Drug Repurposing Is a New Opportunity for Developing Drugs against Neuropsychiatric Disorders.

Authors:  Hyeong-Min Lee; Yuna Kim
Journal:  Schizophr Res Treatment       Date:  2016-03-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.